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Adherence to Analgesics for Cancer Pain: A Comparative Study of African
Americans and Whites Using an Electronic Monitoring Device
Abstract
Despite well-documented disparities in cancer pain outcomes among African Americans, surprisingly
little research exists on adherence to analgesia for cancer pain in this group. We compared analgesic
adherence for cancer-related pain over a 3-month period between African Americans and whites using the
Medication Event Monitoring System (MEMS). Patients (N = 207) were recruited from outpatient medical
oncology clinics of an academic medical center in Philadelphia (≥18 years of age, diagnosed with solid
tumors or multiple myeloma, with cancer-related pain, and at least 1 prescription of oral around-the-clock
analgesic). African Americans reported significantly greater cancer pain (P < .001), were less likely than
whites to have a prescription of long-acting opioids (P < .001), and were more likely to have a negative
Pain Management Index (P < .001). There were considerable differences between African Americans and
whites in the overall MEMS dose adherence, ie, percentage of the total number of prescribed doses that
were taken (53% vs 74%, P < .001). On subanalysis, analgesic adherence rates for African Americans
ranged from 34% (for weak opioids) to 63% (for long-acting opioids). Unique predictors of analgesic
adherence varied by race; income levels, analgesic side effects, and fear of distracting providers predicted
analgesic adherence for African Americans but not for whites. Perspective: Despite evidence of
disparities in cancer pain outcomes among African Americans, surprisingly little research exists on
African Americans' adherence to analgesia for cancer pain. This prospective study uses objective
measures to compare adherence to prescribed pain medications between African American and white
patients with cancer pain.
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Abstract

Author Manuscript

Despite well-documented disparities in cancer pain outcomes among African Americans,
surprisingly little research exists on adherence to analgesia for cancer pain in this group. We
compared analgesic adherence for cancer-related pain over a 3-month period between African
Americans and Whites using Medication Event Monitoring System [MEMS]. Patients (n=207)
were recruited from outpatient medical oncology clinics of an academic medical center in
Philadelphia [≥18 years of age, diagnosed with solid tumors or multiple myeloma, with cancerrelated pain, and at least one prescription of oral around-the-clock analgesic (ATC)]. African
Americans reported significantly greater cancer pain (P<.001), were less likely than Whites to
have a prescription of long acting opioids (P<.001), and more likely to have a negative pain
management index (P<.001). There were considerable differences between African Americans and
Whites in the overall MEMS dose adherence, i.e., percentage of the total number of prescribed
doses that were actually taken (53% vs. 74%, P<.001). On sub-analysis, analgesic adherence rates
for African Americans ranged from 34% (for weak opioids) to 63% (for long acting opioids).
Unique predictors of analgesic adherence varied by race; income levels, analgesic side-effects, and
fear of distracting providers predicted analgesic adherence for African Americans but not for
Whites.
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Introduction
The Institute of Medicine (IOM) report, Relieving Pain in America, finds that one of the
most robust findings on differential pain outcomes pertain to African Americans.16 Previous
IOM reports41, accumulated reviews, 1, 8, 11, 12, 26 and a meta-analysis,23 compelingly
demonstrates that African American patients are less likely to receive analgesia for pain in
cancer and non-cancer settings. There is also strong evidence from studies conducted
independently in different geographical regions in the United States (U.S.) that pharmacies
in predominantly African American and minority zip codes do not carry opioids needed to
treat moderate to severe pain.13,30

Author Manuscript

While provider and system level factors have been documented in the literature, suprisingly
little is known about adherence to analgesia for cancer pain among African Americans. This
issue is important since analgesics remain the predominant and consistently reimbursable
clinical paradigm for managing cancer pain. While the National Comprehensive Cancer
Network guidelines for adult cancer pain31 include a number of complementary and
alternative modalities, they are not consistently reimbursed or lack rigorous data on clinical
effectiveness for cancer pain.4,20 Thus differential analgesic adherence may be
conceptualized as an important explanatory variable in cancer pain outcomes.28

Author Manuscript

The majority of the studies on analgesic adherence for cancer pain have been conducted
predominantly or exclusively with White samples.27, 28, 32, 43, 47, 53, 55 The very limited
existing studies with African Americans are cross-sectional (e.g., computed adherence for
the past 24 hours)38 and are based on self-reported measures of adherence.2, 22, 38, 50 Studies
in non-cancer settings, comparing self-reported measures of adherence with objective
measures such as electronic monitoring, have found that subjective adherence measures are
not sufficiently accurate and overestimate rates of adherence by 10%–30%.3, 7, 10, 14, 19, 54
Thus, we compared analgesic adherence for cancer pain between African Americans and
Whites longitudinally using Medication Event Monitoring System [MEMSTM]. The specific
aims were to:
1.

Compare adherence to prescribed around-the-clock (ATC) analgesic between
African Americans and Whites with cancer-related pain over a 3-month period.

2.

Identify unique predictors of ATC analgesic adherence for cancer pain for African
Americans and Whites.

Methods
Author Manuscript

Design and Study Population
The study was a 3-month observational design with repeated measures at two time-points,
i.e., baseline (T1) and 3-months (T2). Patients were recruited from two outpatient medical
oncology clinics of an academic medical center in Philadelphia between December 2009August 2011. Inclusion was based on self-identified African Americans or Whites, at least
18 years of age, diagnosed with solid tumors or multiple myeloma, with cancer-related pain,
and at least one prescription of oral ATC analgesic. Patients were excluded if they were
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prescribed ATC analgesics using a transdermal system (e.g. fentanyl patch) due to
limitations of MEMS vials. The study was approved by the Institutional Review Board of
the University of Pennsylvania and all patients provided informed consent.
Study Measures

Author Manuscript

Index Analgesic—The information regarding prescribed ATC analgesics (index
medication) was gathered based on patient self-report during the baseline T1 interview and
triangulated with electronic medical records review. Index analgesics were coded according
to the World Health Organization’s (WHO) analgesic ladder. 51, 52 This includes Step 1
(non-opioid analgesics e.g., ibuprofen, acetaminophen, naproxen); Step 2 (weak opioids e.g.,
codeine); and Step 3 (strong opioids (e.g., morphine, oxycodone, methadone). The Step 3
analgesics were further coded according to immediate release and extended or sustained
release (long acting) opioids due to evidence of both differential prescription and use of long
acting opioids by race.50 We computed Pain Management Index (PMI) for each patient
based on WHO guidelines for treating cancer pain.51, 52 The PMI measure is based on the
most potent analgesic prescribed to a patient relative to the level of their reported pain. PMI
is calculated by subtracting patient’s pain levels (“pain worst” score from the Brief Pain
Inventory coded as mild, moderate, or severe) from the most potent analgesia prescribed. A
negative PMI implies inadequate analgesic prescription relative to the reported pain level.

Author Manuscript

MEMS Analgesic Adherence—Analgesic adherence was captured using [MEMSTM
AARDEX Group Ltd]. MEMS is a medication bottle cap with a microprocessor that records
the occurrence and time of bottle opening in real time. The primary measure of ATC
analgesic adherence in our study was “dose adherence” (percentage of the total number of
prescribed doses that were actually taken). For example, if a patient took 60 out of 80
prescribed doses over the study period, ‘dose adherence’ measure would be 75%.
Patients were instructed on the correct use of MEMS bottle during the baseline T1 interview.
A follow-up phone call was made to each participant within 7 days of the T1 to allow
participants to ask any questions they may have about proper usage of the MEMS bottle.
Patients were instructed to use the bottle for the duration of the study period, and only use
the bottle to take the index medication including any refills for the index medication. They
were asked to notify the study staff of any changes in the medication dose or frequency as
well as document this information in a medication log, where they also maintained a record
of any instances of bottle opening other than when taking the index medications.

Author Manuscript

The PowerView software was used to record and compute MEMS adherence. If a frequency
or medication change occurred during the study period, a new medication entry (phase) was
created as a denominator, with the previous phase ending at PowerView’s default time,
2:59am the day of the change and the next phase beginning at 3:00am. If a dosage change
occurred, the average of the two (or more) dosages was reported, and no new phase was
created. If a patient reported (in writing on the event log or verbally with reasonable
certainty during the T2 interview) having taken doses that the bottle did not record, the
events were added to the MEMS data. For example, added events might occur if a patient
took out two pills at one time and took the second later in the day, or if the patient took out 6
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pills for a 3-day trip. Likewise, if a patient reported extra openings for reasons other than
taking the medication, the extra openings were excluded from the MEMS adherence
calculation. Excluded events included accidental openings, openings only to count pills or
refill the bottle.
Also, hospitalization periods were adjusted in the analysis as a non-monitored period
beginning on the calendar day of admission at 3:00am and ending on the calendar day after
discharge at 2:59am. Hospitalization information (including facility name, dates, and
primary and secondary diagnoses) was obtained from self-report between the T1 and T2
dates, self-report at the T2 interview, and review of patient charts. Hospitalization duration
was calculated by subtracting the admission date from the discharge date.

Author Manuscript

Self-reported Analgesic Barriers—Barriers Questionnaire-II49 was used at baseline to
assess patients’ beliefs about management of cancer pain. BQ-II is a 27 item instrument that
elicits pain management concerns in 8 domains: 1) fear of addiction, 2) fear of tolerance, 3)
fear of side effects, 4) fatalism about cancer pain, 5) desire to be a good patient, 6) fear of
distracting health provider from treating cancer, 7) fear that the analgesics impair the
immune system and 8) concern that analgesics may mask ability to monitor illness
symptoms. For each item, the responses range from 0 (do not agree) to 5 (agree very much).
The recommended scoring is based on mean scores on the total scale (27-items) and
subscales. The internal consistency of the scale is excellent at 0.8949.

Author Manuscript

Analgesic Side-effects—Analgesic side-effects were captured at baseline using
Medication Side-effects Checklist (MSEC)48 that elicits information on presence, type and
severity of eight common analgesic side-effects during the past week (0–10; no severityextreme severity). The reported internal consistency reliability (Cronbach’s alpha) is greater
than 0.80.
Pain Severity and Pain Impact—Pain severity and pain impact was measured at
baseline using the Brief Pain Inventory (BPI).9 The tool assesses pain at its worst, least,
average over the past week and pain currently experienced (pain now) on a 0–10 scale (no
pain-pain as bad as you can imagine). The psychometrics of the BPI is well-established with
cancer patients, including minority patients with cancer. Its Cronbach’s alpha ranges 0.77 to
0.91.

Author Manuscript

Intentional vs. Unintentional Non-adherence—Morisky Medication Adherence Scale
(MMAS),29 a structured, 4-item self-report measure was used at baseline to distinguish
between both intentional (active) and unintentional (passive) dimensions of non-adherence.
Statements corresponding to unintentional non-adherence include “I sometimes forget to
take my pain medicine” and “I am sometimes careless about taking my pain medicine.”
Statements that correspond to intentional non-adherence include “When I feel better I
sometimes stop taking my pain medicine” and “If I feel worse when I take the pain
medicine, sometimes I stop taking it.” The participants were asked to indicate the extent to
which they agree with each statement on the MMAS 4-point scale. This score for each of the
four items are aggregated to give a score ranging from 0 to 4, where higher scores indicate
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higher levels of reported adherence.29 MAMS has established concurrent and predictive
validity and its Cronbach’s alpha in different studies have ranged 0.61 to 0.86.
Demographic and Illness Variables—Self-reported demographic data were gathered
on age, gender, self-identified race and ethnicity, marital status, education, income, and type
of health insurance. Illness-related variables collected from patients’ medical records
included type of cancer; stage of cancer, time since cancer diagnosis, past history of drug or
substance abuse, comorbidities, and history of depression.
Statistical Analysis

Author Manuscript

All data were analyzed using SAS version 9.3.40 A prediction model was constructed using
a backward elimination method considering as potential predictors all variables that were
significant at the bivariate level (p-value < 0.2). The backward elimination method involved
starting with all candidate variables in the model, then deleting the variable (if any) that
improves the model the most by being deleted, and repeating this process until no further
improvement is possible (i.e. all remaining variables in the model are significant at the alpha
= 0.05 level).
Separate models were run for African Americans and Whites to understand unique
predictors of analgesic adherence. The rational for running separate models by race rather
than an overall model of adherence was to identify potential intervention targets, which may
be unique to each subgroup.

Author Manuscript

To assess potential bias due to confounding, we generated a series of bivariate analyses with
adherence as the outcome and several key variables obtained at the initial visit as potential
predictors. All variables that were found to be statistically significant at the 0.2 level were
then considered as covariates in the final analysis. Once the multivariable model was
derived, each of the original variables were re-entered into the model, one variable at a time,
by testing the most significant to least significant variable to allow a previously insignificant
variable to become significant in the final model and retaining any variable that yielded a Pvalue < 0.05.
Furthermore, to assess for potential bias due to lost to follow-up at month 3, we created a
binary (yes/no) indicator variable for retention. We then ran a series of bivariate analyses
considering several key variables obtained at the initial visit as potential predictors of
retention status. We found no statistically significant predictors of dropout, which supports
the statistical missing at random data assumption, suggesting no significant bias due to
retention.

Author Manuscript

Sensitivity Analysis for the Observer Effect—A critique of MEMS monitoring is that
due to the awareness of being observed, the MEMS monitoring may lead some individuals
to modify aspects of their medication taking behavior.44, 45 To account for this potential
source of bias, we created two separate variables to determine the internal consistency
between the “dose adherence” outcomes containing data from all the days monitored to the
outcome containing data with the first 30 days of observation removed. The Spearman
correlation between adherence scores for all days monitored and the adherence scores with
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the first 30 days excluded was 0.97 (p < 0.001) for African Americans and 0.95 (p < 0.001)
for Whites.
Because all Spearman correlations were significantly large, there was strong internal
consistency between total adherence scores and the total adherence scores with the first 30
days of observations removed. Similar trends in parameter estimates were observed when
the outcome with first 30 days removed was used with little difference in the available data
between the all monitored data and 30 days of observations removed. Based on this, the
outcome containing the adherence scores for all days monitored was chosen for the final
analysis.

Results
Author Manuscript

Figure 1 presents participant and recruitment flowchart. Adherence data using MEMS were
available for 207 patients (non-Hispanic Whites =121; non-Hispanic African Americans =
86). There was no differential attrition from T1 to T2 based on key variables such as race
(P=0.496) or participants’ general health status (P=0.612). The mean age of the group was
54 years (SD=11). There were significant differences between African Americans and
Whites based on education, income, type of health insurance, and presence of metastasis
(Table 1). However, there were no significant differences between the groups based on age,
gender, type of cancer, time since cancer diagnosis, comorbidity burden, and past history of
substance or alcohol abuse (Table 1).
Pain and Analgesic Prescription

Author Manuscript

When compared to Whites, African Americans reported significantly greater cancer pain
including higher BPI’s “pain worst” scores (P<.001), higher “pain least” scores indicating
lower pain relief (P<.001) and negative PMI indicating inadequate analgesic prescription
given the pain levels (P<.001) (Table 2). There were no differences in African Americans
and Whites in analgesic prescription according to the WHO analgesic step. However, within
WHO Step 3 analgesics, African Americans were less likely to be prescribed long acting
opioids for pain relief (P<.001). There was a significant difference between groups on
Morisky non-adherence items. More specially, a larger percentage of African Americans
reported being forgetful (41% vs. 27%, p= .043) and intentionally stopping to take pain
medicine when feeling better (58% vs. 40%; p= .009).
MEMS Analgesic Adherence

Author Manuscript

Patients’ adherence was monitored for an average of 88 days (SD=17) using MEMS. There
was no difference between African Americans and Whites in the number and frequency of
medication changes during the index period (Table 2). However, there were considerable
differences between African Americans and Whites in the overall analgesic adherence (53%
vs. 74%, P< .001) as well as adherence according to the WHO analgesic step (Table 2). On
sub-analysis, analgesic adherence rates for African Americans ranged from 34% (for weak
opioids) to 63% for long acting opioids. For Whites, adherence ranged from 55% (for weak
opioids) to 78% for long acting opioids (see Figure 2).
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African Americans—Income level was the strongest predictor of analgesic adherence for
cancer pain among African Americans (Table 3). Compared to those who reported a
household income of more than $50,000 a year, those between $10,000 and $50,000 a year
had a 25.89 lower percentage of adherence (P=0.002) and those with less than $10,000 a
year had a 41.83 lower percentage of dose adherence (P< 0.001). Also, clinical variables
were significant in explaining non-adherence in African Americans. For instance, for each
unit increase in the severity of analgesic side effects, the percentage of dose adherence
decreased by 1.39 (P<0.001). Similarly, for each unit increase in the concern of distracting
doctor from curing the disease, the percentage of dose adherence decreased by 7.44 (P=
0.002). The Morisky subscale of intentional non-adherence was also a strong predictor of
dose adherence for African Americans. Those who reported intentional non-adherence (i.e.,
stopping to use analgesics when feeling better), had a −22.17 lower percentage of dose
adherence (P< 0.001). On the other hand, number of analgesic side-effects reported and
number of analgesics prescribed were associated positively with dose adherence. This model
was statistically significant and explained 44% of the variance for dose adherence for
African Americans.

Author Manuscript

Author Manuscript

Tables 3 and 4 present the findings of the unique predictors of overall adherence (dose
adherence) for African Americans and Whites, respectively.

Whites—Intentional non-adherence subscale (i.e., stopping to use prescribed analgesics
when feeling better or worse) was the strongest predictor of dose adherence for Whites
(Table 4). Those who reported stopping to use analgesics when feeling better had a 23.67
lower percentage of dose adherence (P< 0.001). Similarly, those who reported stopping to
use analgesics when feeling worse, had a 18.56 lower percentage of dose adherence (P=
0.010). Clinical variables such as length of pain due to cancer and pain levels also predicted
dose adherence for Whites. For every unit increase in time since cancer diagnosis (in
months), dose adherence increased by 0.16 percent (P=0.026). Whereas for every unit
increase in “pain least” (higher scores indicate lower pain relief), the percentage of dose
adherence decreased by 2.88 (P= 0.041). This model was statistically significant and
explained 30% of the variance for dose adherence for Whites.

Discussion

Author Manuscript

“Drugs don’t work in patients who don’t take them” (C. Everett Koop). By the same token,
not taking medication is a behavioral representation of what may be right or wrong for the
patient in a medication treatment setting. We found that analgesic adherence was low for
both Whites and African Americans but it was considerably lower for African Americans.
Most existing interventions to improve cancer pain outcomes are conceived within a
psychoeducational paradigm, which focuses on knowledge transfer to address attitudes and
barriers to opioid use.17, 39, 42 A systematic review of the effectiveness of such interventions
for cancer pain management found that while the interventions improved knowledge about
cancer pain management in the majority of the studies (73%), most did not improve reported
adherence to analgesics.35 These findings were confirmed in another meta-analysis that
J Pain. Author manuscript; available in PMC 2016 September 01.
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found no benefit of educational interventions on analgesic adherence or pain-related
interference.5 This indicates that the knowledge path to improving analgesic adherence or
cancer pain outcomes may be inadequate.
Consitently, we found that most common analgesic-related fears (including addiction
concerns) did not explain objective analgesic adherence for cancer pain for African
Americans or Whites. Rather, most of the identified predictors of objective adherence may
be thought of as circumstantial or experiential likely based on patients’ previous clinical
experience of cancer pain management or clinician-patient interaction. Further, African
Americans had more of such barriers (e.g., need for more information about pain
medications, and fear of distracting or annoying clinicians, and concern for side-effects)
than Whites.

Author Manuscript

Similar findings were supported in a previous study of adherence to analgesia for cancer
pain (employing subjective measures of adherence and African American patients only).
The authors found that addiction concerns were not correlated with adherence for WHO step
2 or step 3 analgesics; rather pain intensity, side-effects, and fear of distracting clinicians
were associated with analgesic adherence in African Americans with cancer pain.38

Author Manuscript

Similarly, in our study, an increase in the severity of side-effects was associated with lower
adherence to analgesia for African Americans but not for Whites. Moreover, more adherent
African Americans reported greater number of analgesic side-effects at baseline suggesting
disparites in analgesic adverse effects management in African Americans. The higher
burden of side-effects in African Americans may also be related to the choice of analgesics
in African Americans. In a recent study, authors found that controlling for the type of health
insurance, African Americans with cancer pain had 71% lower odds of receiving a
prescription of oxycodone than White patients (P <.001) and they were more likely to be
prescribed morphine even in the presence of renal insufficiency.25 Authors further
demonstrated that the type of analgesics prescribed partially mediated the reported adverse
analgesic effects.25
Among Whites, lower pain relief (higher pain least scores) predicted lower adherence to
analgesia whereas length since cancer diagnosis, possibly indicating disease severity,
predicted greater analgesic adherence. Consistently, in a previous analysis to understand
trade-offs African Americans and Whites employ in making cancer pain decisions, we found
that African Americans were more likely to make analgesic use decisions based on sideeffects whereas Whites were more likely to make analgesic use decisions based on amount
of relief expected from using pain medications.24

Author Manuscript

Another important finding of this study is the strong negtive linear relationship in the levels
of income and adherence to analgesia for cancer pain among African Americans. Studies in
non-pain settings have found that higher out of pocket cost and household income less than
$20,000 are associated with medication non-adhrence behaviors including decreasing the
dose or frequency of medications, failing to refill or extending time between the
refills.15, 36, 37, 46 In the setting where patients refill their pain medications, they may save
pain medications until they cannot stand pain or hoard pain medications for when pain is
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severe; a behavior termed medication triaging.21 While studies of medication triaging in the
context of pain are limited, there is some evidence that patients may be non-adherent to pain
medications in order to be able to afford medications for other chronic conditions such as
diabetes.18 Thus, low income patients may compromise on taking pain medications to be
able to afford medications considered as “more important” or “lifesaving” or even resort to
less expensive but also less potent over-the counter alternative therapies.18, 21

Author Manuscript

The fact that African Americans with lower incomes were less adherent, brings to the
forefront the importance of discussing cost and ability to pay when writing an analgesic
prescription. In the current clinical scenario, management of multiple conditions and
symtoms occur in isolation and by multiple health care providers resulting in accumulated
cost and complexity for the patients. In a national study, majority (two-thirds) of patients
with chronic illnesses reporting underusing medications due to cost-related concerns never
discussed these concerns with their clinicians.37 Of those reporting cost-related nonadhrence said clinicians never asked them about their ability to pay for medications or did
not believe that clinicians could help.37 Clinicians may take a more proactive role in
assessing cost-related issues potentially contributing to analgesic non-adherence and provide
assistance such as reviewing overall medication regimens, simpligying regimens, changing
medications to less expensive alternatives when clinically appropriate, or providing
information about programs that may assist with prescription medication cost.

Author Manuscript

Finally, consistent with Rhee et al., study,38 overuse of analgesia among African Americans
is not supported in our study. Unlike adherence for some other chronic conditions where
there is more agreement on adherence cut-off rates, there is no agreement about which cutoff is valid for analgesic use for cancer pain.34 Previous studies have employed 70%32 to
100%33, 34 and in a non-U.S. study However, regardless of the cut-off used, the analgesic
adherence rates of 34%–63% in African Americans are considerably lower. Similar lower
analgesic adherence rates for cancer pain in African Americans were also identified in
another study (46%)38 even using subjective measures that typically overestimate
adherence. These findings should be a call for concern for the goal of achieving equity in
clinical cancer pain outcomes.
Strengths and Limitations

Author Manuscript

This is the first study to our knowledge that has compared adherence to analgesia for cancer
pain and its unique predictors between African Americans and Whites while employing
objective measures of adherence over time. However, some findings of our study are
limited. First, we limited objective monitoring of analgesics to one ATC analgesic. Since we
used MEMS vial for electronic monitoring, it was not feasible to monitor ATC prescription
in a patch form. However, we have no reason to believe that analgesics in a patch form
would be prescribed disproportionately to African Americans- an assumption that is needed
to nullify our findings of differential prescription of long acting opioids by race.
Furthermore, while MEMS allows for long-term assessment of adherence and detailed
information about patterns of prescription use, it does not guarantee ingestion of medication.
Vial opening other than for medication taking, medication changes within the study period,
and medication holidays (e.g., secondary to hospitalization) may result in inaccuracies in
J Pain. Author manuscript; available in PMC 2016 September 01.
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adherence measurement. We minimized this potential source of bias by accounting for cap
openings other than for medication taking (e.g., for refills), a change in frequency and dose
of analgesics during the study period, or medication holidays due to hospitalizations (see
study measures). Despite these limitations, studies in non-cancer pain setting comparing
MEMS with a variety of subjective measures have concluded that MEMS is one of the more
accurate adherence measurement approaches.6

Author Manuscript

Our study is limited in that there were unmeasured cancer (cancer treatment, medications
other than analgesics and co-analgesics, caner treatment related side-effects, cancer-related
functional impairments), and psychiatric variables (such as cancer-related anxiety, cancer
treatment-related posttraumatic symptoms) that may confound the findings. Furthermore, we
included history of depression from patients’ medical records and did not use self-report
measure of depression. Also, to create predictive models, we used self-reported data from
baseline. Since our main goal was to assess patients’ actual adherence behaviors, we
believed that multiple contacts by the study staff would create an observational effect
resulting in alteration of patient’s actual behavior. It is conceivable that some of the
predictors of interest changed over the 3-month course of the study. Finally, although we
computed PMI for adequacy of analgesic prescription given patient’s levels of pain, we did
not compare doses of analgesics between African Americans and Whites. Despite these
limitations, our findings add to a very scarce body of literature to understand differences in
analgesic adherence and preliminary understanding of sources of those differences as a way
to explain the widely observed clinical disparities in cancer pain outcomes.

Conclusions
Author Manuscript
Author Manuscript

Our salient findings indicate that 1) there are significant disparities between African
Americans and Whites in the treatment of cancer pain and adherence to analgesia captured
using MEMS over a 3-months period; 2) analgesic-related beliefs commonly implicated in
analgesic and opioid-related non-adherence (e.g., addiction concerns) do not explain
objective analgesic taking in both groups; 3) rather, clinical pain management variables
explain objective analgesic adherence in this sample of African Americans and Whites; 4)
the unique predictors of analgesic adherence vary by race, specially socioeconomic
variables, fear of distracting providers, and analgesic side-effects predict analgesic
adherence for African Americans but not for Whites; 5) these additional variables may
explain differential analgesic adherence and consequent disparities in cancer pain outcomes
in African Americans. The greater burden of unmet cancer pain management needs in
African Americans deserves correspondingly greater attention and perhaps greater intensity
of interventions with this group, however, majority of the existing interventions have been
both conceptualized and investigated predominantly with White patients.
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Perspective
Despite evidence of disparities in cancer pain outcomes among African Americans,
surprisingly little research exists on African Americans’ adherence to analgesia for
cancer pain. This prospective study employs objective measures to compare adherence to
prescribed pain medications between African American and White patients with cancer
pain.
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Participant and recruitment flow chart.
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Figure 2.

MEMS Dose Adherence by Race and Type of Analgesic
WHO = World Health Organization
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Table 1

Author Manuscript

Demographic and Illness Characteristics (N=207)
Total (N=207)

Whites (N=121)

African Americans (N=86)

p-values†

Age

54(11)

54(12)

53(10)

.392

Time since cancer diagnosis (months)

37(35)

36(35)

38(36)

.784

4(3)

4(2)

4(3)

.260

Male

90(43)

59(49)

31(36)

.069

Female

117(57)

62(51)

55(64)

Variable
Mean (SD)

Charlson Comorbidity Index
Frequency (%)
Gender

Marital Status

<.001

Author Manuscript

Married

110(53)

84(69)

26(30)

Separated/Divorced/Widowed

56(27)

19(16)

37(43)

Never Married

41(20)

18(15)

23(27)

Education

.016

Elementary

3(1)

1(1)

2(2)

High School

70(34)

35(29)

35(41)

College/Trade School

101(49)

58(48)

43(50)

More Than College

33(16)

27(22)

6(7)

Income (US$)

<.001

Author Manuscript

< 30, 000

73(35)

24(20)

49(57)

30–50,000

36(17)

15(12)

21(24)

50–70,000

37(18)

26(21)

11(13)

70–90,000

24(12)

21(17)

3(3)

>90,000

37(18)

35(29)

2(2)

Private

107(52)

81(68)

26(30)

Medicaid

27(13)

5(4)

22(26)

Medicare

41(20)

21(18)

20(23)

Multiple

25(12)

12(10)

13(15)

6(3)

1(1)

5(6)

Health Insurance

Other

<.001

Cancer Type

.907

Author Manuscript

Lung

32(15)

21(17)

11(13)

Breast

38(18)

21(17)

17(20)

Gastrointestinal

31(15)

19(16)

12(14)

25(12)

15(12)

10(12)

Multiple Myeloma

34(16)

17(14)

17(20)

Other Solid tumors

47(23)

28(23)

19(22)

Genitourinary/Reproductive
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Variable

Total (N=207)

Whites (N=121)

African Americans (N=86)

Author Manuscript

Presence of Metastasis

p-values†
.008

Yes

148 (72)

95 (78)

53 (62)

No

59 (28)

26 (22)

33 (38)

Yes

35(17)

16(13)

19(22)

No

172(83)

105(87)

67(78)

History of Substance Abuse

.131

History Alcohol Abuse

.636

Yes

20(10)

13 (11)

7(8)

No

187(90)

108 (89)

79(92)

History of Depression

.236

Yes

87(42)

55(45)

32(37)

No

120(58)

66(55)

54(63)

Author Manuscript

†

p-values are based on t-tests for continuous variables and chi-squared for categorical variables.

WHO =World Health Organization
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Table 2

Author Manuscript

Analgesic Prescription and Pain Management Variables (N=207)
Variable

Total (N=207)

Whites (N=121)

African Americans (N=86)

p-values†

Frequency (%)
Index Analgesic

.111

WHO Step 1

19 (9.2)

7 (5.8)

12 (14.0)

WHO Step 2

22 (10.6)

12 (9.9)

10 (11.6)

WHO Step 3

166 (80.2)

102 (84.3)

64 (74.4)

Negative Pain Management Index

<.001

Author Manuscript

Yes

18 (8.7)

5 (4.13)

13 (15.1)

No

189 (91.3)

116 (95.9)

73 (84.9)

Prescription of long acting opioids

<.001

Yes

117 (56.5)

82 (67.8)

35 (40.7)

No

90 (43.5)

39 (32.2)

51 (59.3)

Yes

68 (32.9)

33 (27.3)

35 (40.7)

No

139 (67.1)

88 (72.7)

51 (59.3)

MMAS unintentional; forgetfulness
0.043

MMAS unintentional; carelessness

Author Manuscript

Yes

35 (16.9)

21 (17.4)

14 (16.3)

No

172 (83.1)

100 (82.6)

72 (83.7)

0.839

Yes

98 (47.3)

48 (39.7)

50 (58.1)

No

109 (52.7)

73 (60.3)

36 (41.9)

Yes

34 (16.4)

19 (15.7)

15 (17.4)

No

173 (83.6)

102 (84.3)

71 (82.6)

Pain worst (BPI, 0–10)

6.4(3)

5.9(3)

7.0(2)

<.001

Pain least (BPI, 0–10)

3.3(2)

2.8 (2)

4.0(2)

<.001

Pain average (BPI, 0–10)

4.7(2)

4.1(2)

5.3(2)

<.001

Pain interference (BPI, 0–70)

35.2(16)

33.6 (15)

37.6(16)

.086

Severity of side-effects (MSEC, 0–80)

25.2 (15)

23.8 (13)

27.1(17)

.130

MMAS intentional; stop when feel better
0.009

MMAS intentional; stop when feel worse
0. 739

Mean (SD)

Author Manuscript
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Total (N=207)

Whites (N=121)

African Americans (N=86)

p-values†

Barriers Questionnaire (BQ-II, 0–135)

66.8 (20)

64.5(19)

70.0 (21)

.052

Number of index medication changes during the study
period

.05 (0.24)

.06 (0.23)

.05 (0.26)

.744

Number of medication frequency changes during the study
period

.14 (0.40)

0.18 (0.46)

.09 (0.29)

.094

Total number of analgesics prescribed (excluding coanalgesics)

2.1 (0. 80)

2.1 (0.79)

2.0 (082)

.711

Total number co-analgesics prescribed

0.24 (0.50)

0.24 (0.51)

0.23 (0.47)

.920

% Overall adherence

65.1 (34.5)

73.7 (31.5)

52.8 (34.9)

<.001

Number of MEMS days monitored

87.6(16.7)

86.8 (15.5)

88.4(17.9)

.486

WHO Step 1

50.6 (33.5)

59.5 (37.5)

45.4 (31.5)

.391

WHO Step 2

45.2 (31.8)

54.9 (28.6)

33.6 (33.0)

.121

WHO Step 3

69.3 (33.7)

76.9 (30.7)

57.3 (35.1)

.000

73.6 (31.0)

78.1 (29.2)

62.9 (32.9)

.015

Variable

Author Manuscript
Author Manuscript

% Adherence by WHO step

% Adherence by long acting opioids only
†

p-values are based on t-tests for continuous variables and chi-squared for categorical variables.

BPI= Brief Pain Inventory; Morisky Medication Adherence Scale; MSEC= Medication Side-effects Checklist; BQ= Barriers Questionnaire; WHO
=World Health Organization
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Table 3

Author Manuscript

Unique Predictors of Analgesic Adherence for African Americans
Beta Coefficients*

Standard Error

P-Value

<$10,000

−41.828

9.207

<0.001

$10,000–$50,000

−25.894

8.188

0.002

>$50,000 (reference)

------

------

------

Yes

25.629

9.381

0.008

No (reference)

------

------

------

Yes

−22.174

6.131

<0.001

No (reference)

------

------

------

Total number of analgesics prescribed (excluding co-analgesics)

10.720

3.836

0.007

Number of analgesic side-effects

9.812

2.675

<0.001

Fear that if doctors have to deal with pain they won’t concentrate on curing the disease
(0 = do not agree at all, 5 = agree very much)

−7.440

2.256

0.002

Fear that doctors might find it annoying to be told about pain (0 = do not agree at all, 5
= agree very much)

5.911

2.394

0.016

Severity of analgesic side-effects

−1.389

0.406

<0.001

Variable
Household Income

Feel the need to receive further information about pain medication

Intentional non-adherence (When I feel better I sometimes stop taking my pain
medicine)

Author Manuscript

Model: (F(9,76) = 6.65, p < 0.001, R2 = 0.441)

Author Manuscript

MEMS =Medication Event Monitoring System
*

The beta coefficients from the final prediction model represent slope coefficients for the continuous predictors, and the difference from the
reference category for the categorical predictors. A large value implies a large effect size.
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Table 4

Author Manuscript

Unique Predictors of Analgesic Adherence for Whites
Variable

Author Manuscript

Beta coefficients

Standard Error

P-Value

Yes

−23.672

5.315

<0.001

No (reference)

------

------

------

Yes

−18.557

7.054

0.010

No (reference)

------

------

------

Pain “least” in last week (0 = no pain, 10 = pain as bad as you can imagine)

−2.876

1.394

0.041

Length it has been since the diagnosis of cancer (months)

0.160

0.071

0.026

Intentional non-adherence (when I feel better I sometimes stop taking my pain medicine)

Intentional non-adherence (if I feel worse when I take the pain medicine, sometimes I
stop taking it)

Model: (F(4,116) = 12.34, p < 0.001, R2 = 0.299)
MEMS =Medication Event Monitoring System
*

The beta coefficients from the final prediction model represent slope coefficients for the continuous predictors, and the difference from the
reference category for the categorical predictors. A large value implies a large effect size.
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